National Comprehensive Cancer Network



Educational Events & Programs

Thank you very much for attending this Policy Summit!

NCCN POLICY SUMMIT UPDATES  > Article to be published in Spring of 2018.

On December 1, 2017, the National Comprehensive Cancer Network®(NCCN®) hosted a Patient Advocacy Summit focused on addressing survivorship issues in cancer care. In preparation for the Patient Advocacy Summit, NCCN conducted an environmental scan of existing and emerging aspects of survivorship through stakeholder meetings with survivors and various patient advocacy groups to discuss needs, opportunities, and challenges in providing high-quality, patient-centered care for all cancer survivors. The corresponding patient advocacy summit reported on the findings of the stakeholder meetings and included discussions by the multi-stakeholder, multi-disciplinary larger cancer care community. These stakeholders perspectives are imperative to fully understand the challenges of survivorship planning to improve the quality of, and access to, cancer care and in addressing post-treatment needs.

A subsequent article of the summit will be published in the Journal of the National Comprehensive Cancer Network―JNCCN.

Please check back often for additional updates regarding the summit. If you have any questions, please contact James McCanney.

This activity is supported by: Adaptive Biotechnologies; AmerisourceBergen; Apobiologix, a division of ApoPharma USA, Inc.; Astellas; Gilead Sciences, Inc.; HELSINN; ImpediMed; Incyte Corporation; Janssen Oncology; Kite, a Gilead Company; Shire; Taiho Oncology; and Takeda Oncology. This activity is sponsored by: Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Biomedical, Inc.; Bristol-Myers Squibb; Celgene; Clovis Oncology, Inc.; Dendreon; Novartis Pharmaceuticals Corporation; and Sandoz, A Novartis Division. This activity is supported by an educational donation provided by Amgen. Supported by AstraZeneca through its NCCN Corporate Council Membership. Supported by an unrestricted grant from Eisai. Supported by a grant from Genentech, a Member of the Roche Group. This activity is supported by a contribution from Lilly. Supported by an independent educational grant from Merck & Co., Inc. This activity was made possible by Pharmacyclics LLC and Janssen Biotech, Inc. Supported by an unrestricted sponsorship from TESARO.


Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.

NCCN offers organizations various supporter opportunities.